supplemental method to treat breast cancer

Doug Skrecky (
Wed, 4 Nov 1998 13:50:23 -0800 (PST)

After looking through my files for the uses of supplements as an adjunctive treatment for breast cancer, I was intrigued by the breast tumor regression effect of high dose (390 mg/day) coenzyme Q10. A full double blind placebo controlled trial of this supplement in the treatment of breast cancer has apparently not been done, probably (IMHO) because this is not a patentable (read profitable) drug. However the existing data is encouraging. Following is an abstract I typed in of one report.

Biochemical and Biophysical Research Communications 212(1): 172-177 July 6, 1995
"Progress on Therapy of Breast Cancer With Vitamin Q10 and the regression of Metastases"


Over 35 years, data and knowledge have internationally evolved from biochemical, biomedical and clinical research on vitamin Q10 (coenzyme Q10; CoQ10) and cancer, which led in 1993 to overt complete regression of the tumors in two cases of breast cancer. Continuing this research, three additional breast cancer patients also underwent a conventional protocol of therapy which included a daily oral dosage of 390 mg of vitamin Q10 (bio-quinone of Pharma Nord) during the complete trials over 3-5 years. the numerous metastases in the liver of a 44-year-old patient "disappeared", and no signs of metastases were found elsewhere. a 49-year-old patient, on a dosage of 390 mg of vitamin Q10, revealed no signs of tumor in the pleural cavity after six months, and her condition was excellent. A 75-year-old patient with carcinoma in one breast, after lumpectomy and 390 mg of CoQ10, showed no cancer in the tumor bed or metastases. Control blood levels of CoQ10 of 0.83-0.97 and of 0.62 microgram/ml increased to 3.34-3.64 and 3.77 microgram/ml, respectively, on therapy with CoQ10 for patients A-MRH and EEL.

Additional quote from the above research report:

"previously observed that a dose level of 90 mg of CoQ10 in breast cases for ca 8 months was ineffective, since only 6 of the 32 breast cases showed even a hint of possible clinical regression on CoQ10."